CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Latest Progress, Future Possibilities, and Implications for Patient Care

Deepen your understanding on guideline concordant treatment for early or metastatic HR-positive/HER2-negative breast cancer, with a focus on the appropriate use of CDK4/6 inhibitors and toxicity management related to these therapies, through on-demand webcasts with accompanying slides and an expert-written ClinicalThought commentary.

Share

Program Content

Events

  • Live Event CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Latest Progress, Future Possibilities, and Implications for Patient Care
    CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Latest Progress, Future Possibilities, and Implications for Patient Care
    Congratulations: You achieved a completion on 04/09/2022

    You can enroll in the following live event(s) on this topic.

Activities

Adjuvant Therapy for EBC
Individualizing Adjuvant Therapy for HR-Positive/HER2-Negative EBC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 04, 2024

Expires: October 03, 2025

Managing AEs and Adherence to CDK4/6 Inhibitors
Strategies for Managing AEs and Promoting Adherence to CDK4/6 Inhibitors
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 04, 2024

Expires: October 03, 2025

CDK46 Inhibitor to Treat Breast Cancer
CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Individualizing Therapy for HR-Positive/HER2-Negative MBC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: October 09, 2024

Expires: October 08, 2025

Faculty

cover img faculity

Jamie L. Carroll, APRN, CNP, MSN

Assistant Professor of Medical Oncology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Elizabeth Diaz, PA-C

Physician Assistant
Medical Oncology
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas

cover img faculity

Julia A LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
UCLA Hematology Oncology
Santa Monica, California

Provided by

ProCE Banner

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner